Drug Overview
Iressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal and cancer cells, and plays an important role in cell growth and proliferation. EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer. Iressa inhibits the kinase activity of del19 or exon 21 point mutation L858R mutations, preventing phosphorylation of tyrosine residues associated with the receptor, resulting in the inhibition of EGFR-dependent proliferation.
Iressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal and cancer cells, and plays an important role in cell growth and proliferation. EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer. Iressa inhibits the kinase activity of del19 or exon 21 point mutation L858R mutations, preventing phosphorylation of tyrosine residues associated with the receptor, resulting in the inhibition of EGFR-dependent proliferation.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Iressa : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 99: The authors drug assessment summary for lorlatinib in non-small cell lung cancer
Figure 100: Lorlatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 101: Seribantumab for non-small cell lung cancer – SWOT analysis
Figure 4: Iressa sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Iressa drug profile
Table 2: Iressa pivotal trial data in non-small cell lung cancer
Table 3: Iressa late-phase trial data in non-small cell lung cancer
Table 4: Iressa sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Iressa patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
